Market Outlook
The global cancer biomarkers market, valued at USD 24.5 billion in 2025, is projected to reach USD 25.9 billion in 2026 and USD 37.8 billion by 2035, representing a CAGR of 4.3% during the forecast period 2026 to 2035.
To learn more about this report, request a free sample copy
Market Report: Key Takeaways
Market Size & Trends
- In terms of type of biomarker, the HER2 biomarkers currently secure 21.1% of the overall revenue share, owing to its high clinical validation and widespread use in breast and gastric cancer.
- In terms of the type of cancer, breast cancer testing solutions hold around 25.1% of the market share, due to rising burden of breast cancer and the need for early detection.
- In terms of geographical regions, North America holds around 52.1% of the current market share; it has relatively higher number of manufacturing facilities, compared to other regions.
Key Market Statistics
- Market Size in 2026: $ 25.9 Billion
- Estimated Market Size in 2035: $ 37.8 Billion
- CAGR (2026-2035): 4.3%
- North America: Largest market in 2026
Market Introduction
Over the last couple of decades, researchers and companies have introduced several advanced and effective cancer treatment options in the market, including targeted therapies, immunotherapies, and certain anti-cancer vaccines. Despite these advancements, cancer studies continue to face challenges, such as systemic treatment toxicities, elevated clinical trial attrition, and diverse pharmacological or therapy-specific constraints. These challenges emphasize the urgent need for more precise diagnostic frameworks to improve patient outcomes and reduce the economic burden of therapy failure.
To fulfill this critical unmet need, healthcare industry has widely adopted cancer biomarkers as the cornerstone of modern diagnostic strategy. The necessity for these indicators stems from the molecular heterogeneity of cancer, wherein patients with identical cancer type and disease stage present different molecular / genetic profiles and consequently respond differently to recombinant drugs or biologic therapies. To address this challenge, drug developers and healthcare professionals have shifted toward oncology precision medicine. By identifying specific molecular signatures, healthcare providers can now tailor treatments to the individual, moving away from the traditional “one-size-fits-all” model.
While single analyte biomarkers such as PD-L1, BRAF, and EGFR remain foundational, they often fail to predict long-term efficacy across complex genomic structures. Consequently, the rise of high-throughput tools (specifically next-generation sequencing) has enabled the validation of more comprehensive indicators, including tumor mutation burden (TMB) and microsatellite instability (MSI). These advanced markers provide a deeper understanding of genomic instability, allowing for more accurate therapeutic matching.
This robust pipeline of validated biomarkers is currently the primary catalyst for market expansion. With major pharmaceutical players aggressively investing in multi-omics clinical initiatives, the cancer biomarkers market is poised for significant growth, redefining the standard of care through data-driven diagnostic integration.
Market Segmentation
Based on our market research, we have segmented the cancer biomarkers market forecast into type of biomarker, type of cancer and geographical regions.
By Type of Biomarker
- HER2
- MET
- EGFR
- PD-L1
- NTRK
- ALK
- Other Biomarkers
By Type of Cancer
- Breast Cancer
- Colorectum Cancer
- Lung Cancer
- Prostate Cancer
- Thyroid Cancer
- Bladder Cancer
- Melanoma
- Non-Hodgkin Lymphoma
- Endometrial Cancer
- Kidney Cancer
- Leukemia
By Geographical Regions
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and North Africa
Cancer Biomarkers Market Key Insights
What are the Key Drivers for Cancer Biomarkers Market Growth?
- Rising Global Prevalence and Burden of Cancer: The increasing incidence of various types of cancers worldwide, driven by factors like aging populations, lifestyle changes, and environmental exposures, propels the market growth of cancer biomarkers.
- Rapid Technological Advancements: Rapid progress in technologies, such as next-generation sequencing (NGS), liquid biopsies, omics (including genomics, proteomics), bioinformatics, and artificial intelligence-powered diagnostics simplified biomarker discovery, validation, and clinical application.
- Research and Development Investments and Regulatory Approvals: Big pharmaceutical companies, like Roche and Novartis, invest in cancer biomarker-driven clinical trials, accelerating market growth. Further, regulatory agencies approve companion diagnostics and expand immunotherapy applications are further supporting the domains upward trajectory.
- Growing Adoption of Precision Oncology and Personalized Medicine: Healthcare systems and oncology practices are increasingly shifting toward precision oncology models where treatment decisions are guided by individual tumor biology and molecular profiling. This growing adoption is driven by advances in genomic sequencing, next-generation diagnostics, companion tests, and targeted therapies, which allow doctors to match patients with more effective, less toxic options. As a result, outcomes improve, side effects decrease, and survival rates rise in many cancers.
What are the Main Challenges in Market Growth?
- High research and development costs: Companies invest substantial capital and face extended timelines to discover, validate, and gain regulatory approval for reliable biomarkers, which limits participation especially from smaller firms and delays new product introductions.
- Technical issues with sample collection and storage: Improper handling leads to degradation, contamination, or inconsistencies that reduce test accuracy and cause false results; thereby, undermining clinical trust in biomarker-based diagnostics.
- Limited clinical validation and data standardization: Many new biomarkers lack robust, large scale clinical validation in patient populations, making it difficult to demonstrate consistent clinical utility. Coupled with heterogeneous data formats, assay protocols, and reporting standards across laboratories and studies, hampers data integration, meta analyses, and broad adoption in routine oncology practice.
- Regulatory complexity: Navigating diverse and evolving regulatory pathways for biomarker based tests and companion diagnostics across regions (e.g., FDA, EMA, emerging market agencies) creates uncertainty, increases time to market, and raises compliance costs.
Recent Developments in Cancer Biomarkers Market
- In March 2026, Illumina entered into collaboration with Labcorp to advance precision oncology testing capabilities. Further, the projects are expected to include promoting equitable access to cancer biomarker testing for cancer patients.
- In December 2025, Lunit partnered with Daiichi Sankyo to accelerate biomarker discovery and optimize translational research by integrating its multiple AI-powered Lunit SCOPE digital pathology products across its two oncology pipeline programs.
- In October 2025, Tempus AI collaborated with Whitehawk Therapeutics to leverage its proprietary real-world dataset to advance biomarker-driven research and support the development of latter company’s oncology pipeline.
Industry Experts on Cancer Biomarkers Market Trends
The market for cancer biomarkers is poised for remarkable transformation and sustained growth in the coming years, driven by the surging adoption of cancer biomarker solutions as a preferred non-invasive tool for early cancer detection.
Kirill Shur (Business Manager, CeGat, Germany) stated, “liquid biopsy testing has gained immense popularity owing to its ability to detect cancer in its early stages, and its less invasive nature as compared to the standard biopsies, surgical biopsies or needle biopsies. However, researchers encounter some challenges associated with liquid biopsy testing, such as the low amount of tumor DNA in blood cells, which makes it difficult to detect and analyze biomarkers. To overcome these obstacles, researchers need to focus on the most important biomarkers and regularly update the gene panels by adding or removing biomarkers, whenever required.”
Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following discussions:
- Chief Technical Officer and Former Director of Preclinical Development & Strategic Partnerships, Small Company, US
- Business Manager, Mid-sized Company, Germany
- Former Chief Scientific Officer, Large Company, US
Industry Experts on Cancer Biomarkers Market
The market report includes transcripts of the following other third-party discussions:
- Doctor of Medicine, Research Organization, US, North America
- Professor, Research University, UK, Europe
- Doctor of Medicine, Research Organization, US, North America
- Professor, Research University, US, North America
- Doctor of Medicine, Research Organization, US, North America
- Professor, Research University, US, North America
- Oncologist, Hospital, US, North America
- Professor, Research University, US, North America
- Lead of Cancer Genomics, Research University, Australia, Asia-Pacific
- Professor, Research University, US, North America
Market Share Insights
Which Type of Biomarker Testing Accounts for the Largest Share in the Cancer Biomarkers Market?
- In 2026, HER2 biomarkers testing solutions capture maximum share (21.1%). This is primarily because researchers extensively validate it for diagnosing and predicting the progression of breast and gastric tumors. Companies further reinforce this dominance by associating it directly with multiple high value targeted therapies (such as trastuzumab and pertuzumab), which sustain robust global demand for HER2 testing.
- Conversely, it is anticipated that the EGFR segment will grow at a relatively faster pace. This is attributed to the increasing prevalence of lung cancer coupled with healthcare providers rising adoption of precision oncology and targeted therapies (such as EGFR inhibitors like Osimertinib) that rely on EGFR mutation testing for patient selection in non-small cell lung cancer.
Regional Analysis: Which Regions are Showing the Fastest Growth in Cancer Biomarkers Testing Domain?
North America: Dominating the Market by Securing Highest Share
North America dominates the market for cancer biomarkers, accounting for 52.1% of the overall revenue share in 2026. Increased cancer burden in North America, advanced healthcare infrastructure and increased focus on personalized medicines is boosting the demand for cancer biomarkers in the region.
Which Type of Cancer Holds the Highest Share in the Market?
- According to the cancer biomarkers market forecast, the cancer biomarker tests for breast cancer capture maximum share (25.1%) of the overall market revenue. This can be attributed to the fact that breast cancer is one of the primary causes of cancer related deaths in women, driving the need for specific biomarkers for prognosis, risk prediction, and personalized treatments.
- In future, the cancer biomarker tests for melanoma are likely to grow at a relatively faster pace (CAGR of 4.5%). This can be attributed to the rising global incidence of melanoma, advancements in targeted therapies (such as BRAF and MEK (Mitogen-Activated Protein Kinase Kinase) inhibitors) and increasing adoption of precision diagnostics like BRAF (B-Raf proto-oncogene, serine/threonine kinase) mutation testing and liquid biopsy-based biomarkers.
Scope of Cancer Biomarkers Market Report
| Key Report Attributes |
Details |
| Historical Trend |
Since 2021 |
| Forecast Period |
Till 2035 |
| Market Size 2026 |
$ 25.9 Billion |
| Market Size 2035 |
$ 37.8 Billion |
| CAGR (Till 2035) |
4.3% |
| Segments Covered |
- Type of Biomarker
- Type of Cancer
- Geographical Regions
|
| Key Players Profiled |
- ARUP Laboratories
- Asper Biogene
- BioReference
- Caris Life Sciences
- CeGaT
- Foundation Medicine
- Genekor Medical
- Guardant Health
- IQVIA Laborateries
- Labcorp
- MedGenome
- NeoGenomics Laboratories
- Nonacus
- OncoDNA
- Quest Diagnostics
- Oxford Gene Technology
- Personal Genome Diagnostics
- PhenoPath
- Positive Biosciences
- Tempus
- Thermo Fisher Scientific
- YuceBio
(A complete list of companies captured is available in the report) |
| PowerPoint Presentation (Complimentary) |
Available |
| Customization Scope |
15% Free Customization |
| Excel Data Packs (Complimentary) |
Available |
Frequently Asked Questions
Question 1: What are cancer biomarkers?
Answer: Cancer biomarkers are biological molecules present in blood, tissues, or other fluids. They reveal the presence of cancer and track its progression. Clinicians rely on these biomarkers to diagnose cancer, evaluate risk, and monitor disease progression.
Question 2: What are the most common cancer biomarkers?
Answer: The most common biomarkers are microsatellite instability (MSI), tumor mutational burden (TMB), single nucleotide variants (SNV), copy number variants (CNV) and insertions and deletions (Indels).
Question 3: How big is the cancer biomarker market?
Answer: The market size for cancer biomarkers is estimated to be worth $25.9 billion in 2026.
Question 4: What is the growth rate (CAGR) of the cancer biomarkers market?
Answer: Market for cancer biomarkers is likely to grow at an annualized rate of 4.3% during the forecast period 2026 to 2035.
Question 5: What are the 7 types of biomarkers?
Answer: The 7 types of biomarkers are susceptibility / risk, diagnostic, prognostic, monitoring, predictive, pharmacodynamic / response, and safety biomarkers.
Question 6: Who are the top 10 oncology companies in the world?
Answer: Roche, Bristol-Myers Squibb, Johnson & Johnson, Pfizer, AstraZeneca, Merck & Co., Novartis, AbbVie, Eli Lilly, and Astellas.
